Synthesis and surface modification of mesoporous silica nanoparticles and its application as carriers for sustained drug delivery

Figures & data

Figure 1. Procedure for SBA-15 synthesis.

Figure 2. Schematic of amine functionalization of SBA-15.

Figure 3. SEM images of soxhlet (A) and calcined (B) SBA-15.

Figure 4. (A) N₂ adsorption–desorption isotherms and (B) corresponding BJH pore size distribution curves of pure SBA-15.

Table 1. Structural parameters of SBA-15.

Support	SBET (m^2/g)	dp (A°)	Vp (ml/g)	d1 0 0 (A°)	bp (A°)
SBA-15	479	35.8	0.51	87	32.4

S_BET, BET-specific surface area; V_p, specific pore volume; d_p, average pore diameter, obtained from BJH adsorption data, d_p = 4V_p/S_BET; d_{1 0 0}, XRD interplanar spacing; b_p, pore wall thickness, b_p = (a₀ − d_p)/2, a₀ = (2/√3)d_{1 0 0}.

Figure 5. XRD pattern of SBA-15.

Figure 6. FTIR spectra of SBA-15 before and after calcination, and amine functionalized SBA-15.

Figure 7. TGA curves of as synthesized, calcined, Soxhlet (2 days), Soxhelt (3 days) SBA-15 (A). DTA and TGA analysis of SBA-15-NH₂ (B).

Figure 8. Effect of soaking time on drug loading efficiency while the other conditions were maintained (25 °C, n-hexane solvent).

Figure 9. Effect of temperatures on loading efficiencies while the other conditions were maintained (35 h, n-hexane solvent).

Figure 10. The effect of Ibuprofen/SBA-15 ratio on loading efficiency while the other conditions were maintained (35 h, 40 °C, n-hexane solvent).

Figure 11. Interaction of Ibuprofen and SBA-15-NH₂.

Table 2. Drug loading efficiencies (%) of the synthesized samples.

Sample	SBA-15(SY)	SBA-15	SBA-15-NH2
DL%	30	40	51

Figure 12. Cumulative release (CR) % of Ibuprofen from SBA-15-NH₂ at different pH in SBF medium.

Figure 13. Cumulative release (CR) % of Ibuprofen from (A) SBA-15 (SY), SBA-15 and SBA-15-NH₂ untile 8 h, (B) SBA-15-NH₂ at 260 h.